GABAergic mechanisms in morphine-induced hypothermia

Morphine produced a hypothermic effect in restrained rats which was antagonized by naloxone. This effect was completely inhibited by gamma-acetylenic-GABA, an inhibitor of GABA transaminase and by baclofen, a specific GABAB agonist. Pretreatment with diazepam, an agonist of the benzodiazepine receptor, partially inhibited morphine-induced hypothermia. Flumazenil, a benzodiazepine receptor blocker, potentiated the action of morphine on body temperature. A role of brain GABA in the thermoregulatory effects of morphine is proposed on the basis of these results.     

On the mechanism(s) of morphine-induced hypothermia

The effects of morphine on core body temperature of mice in the presence or absence of catecholamine receptor antagonists were examined. Administration of different doses of morphine (20, 30 and 40 mg/kg) to mice caused a hypothermic effect. Pre-treatment of animals with the opioid receptor antagonist naloxone (1, 1.5 and 3 mg/kg), the D-2 receptor antagonists sulpiride (25 and 50 mg/kg), pimozide (0.0625, 0.125 and 0.25 mg/kg) and the adenosine receptor antagonist theophylline (25 and 50 mg/kg) decreased the morphine-induced hypothermia. The D-1 receptor antagonist SCH 23390 (0.1 and 0.2 mg/kg), the peripheral D-2 antagonist domperidone (10 and 30 mg/kg), the serotonin (5-HT) antagonist methysergide (5 and 10 mg/kg), the adrenoceptor antagonist phenoxybenzamine (2.5 and 5 mg/kg) and the β-adrenoceptor antagonist propranolol (5 and 10 mg/kg) did not inhibit the morphine response. The antimuscarinic drug atropine (5 and 10 mg/kg) caused a slight decrease in the morphine response. In animals pre-treated with reserpine (5 mg/kg), a hyperthermic response was observed after morphine injection. It is concluded that indirect dopaminergic or adenosine receptor mechanism(s) may be involved in the morphine-induced hypothermia in mice.     

PKC and PKA inhibitors reverse tolerance to morphine-induced hypothermia and supraspinal analgesia in mice

Morphine antinociceptive tolerance in the tail-flick test is completely reversed by inhibitors of protein kinase C (PKC) or cAMP-dependent protein kinase (PKA). The effects of these inhibitors on tolerance to supraspinally mediated antinociception, such as the hot-plate test was unknown, as well as their effects in tests of mechanical nociception. The PKC inhibitors bisinolylmaleimide I ((2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide) and G?-7874 [2[1[(3-Dimethylaminopropyl)-5-methozyindol-3-yl]-3-(1H-indol-3-yl) hydrochloride] completely reversed the tolerance to morphine in both the hot-plate and tail-pinch tests. Similarly, the PKA inhibitor KT-5720 (8R, 9S, 11S)-(-)-9-hydroxy-9-hexoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo[a,g]cycloocta[cde]trinden-1-one also reversed tolerance in both tests. The role of PKC and PKA in mediating tolerance to morphine-induced hypothermia was also investigated. Bisinolylmaleimide I, G?-7874 and KT-5720 only partly reversed the 32-fold level of tolerance induced by the morphine pellets. However, co-administration of bisinolylmaleimide I with KT-5720 or G?-7874 with KT-5720 completely reversed the tolerance. This demonstrates that tolerance in a non-behavioral system involves the actions of PKC and PKA.     

Overview. Cholecystokinin and eating

This review focuses on the satiating effect of cholecystokinin (CCK) in humans. Current evidence supports a role for the peptide as a physiological satiety factor. The therapeutic potential of CCK analogs cannot be estimated until further studies are performed that demonstrate the efficacy of analogs for decreasing body weight, and the safety of CCK when administered chronically. Because the brain-gut axis is so important in the normal control of food intake, a great deal of caution is needed, particularly with agents that will presumably be taken for prolonged periods. Even so, at present it seems likely that we will see the introduction of CCK analogs or CCK antagonists as a new class of appetite-modulating agents in the not-too-distant future.     

Effect of selective monoamine oxidase inhibitors on the morphine-induced hypothermia in restrained rats

Morphine (30 mg/kg i.p.) produced a hypothermic effect in restrained rats which was antagonized by naloxone pretreatment (10 mg/kg s.c.). This hypothermia was inhibited by deprenyl pretreatment (5 mg/kg i.p.) and by beta-phenylethylamine treatment (25 mg/kg i.p.). However, the effect of morphine was partially potentiated when a higher dose of deprenyl (10 mg/kg i.p.) was administered. Pretreatment with clorgyline (1 mg/kg i.p.) potentiated the morphine-induced hypothermia. In contrast, the effect of morphine was antagonized when a higher dose of clorgyline was used (5 mg/kg i.p.). Based on these results, a possible role of brain serotonin and dopamine in the thermoregulatory effects of morphine is proposed in this paper.     

Pallidal substrate of morphine-induced locomotion.

Bilateral microinjections of morphine hydrochloride (5.0; 7.5; 10.0 micrograms/0.5 microliters/side) or saline were infused into 3 different regions (dorsal, medial, ventral) of the rat globus pallidus, to examine their effects on locomotor activity. Locomotor activity of each rat was measured 45 min before and 90 min after saline or morphine pallidal microinjections. Morphine induced a dose-dependent increase in locomotion. This increase in locomotion was also significantly different between the 3 pallidal regions. Pretreatment with naloxone (1 mg/kg, sc) inhibited the morphine (7.5 micrograms) hyperlocomotion elicited from all three pallidal areas. The results suggest that the entire pallidum serves as substrate of morphine hyperlocomotion mediated by opiate receptors.     

Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide.

In view of the recently demonstrated extra-endocrine central actions of hypothalamic releasing hormones, we have investigated the effects of prolyl-leucyl-glycinamide (PLG) and thyrotropin releasing hormone (TRH) on morphine-induced catalepsy. Although acute administration of PLG (10 mg kg-1 s.c.) slightly attenuated the cataleptic response, chronic PLG treatment (10 mg kg-1 s.c. for 10 days) virtually abolished morphine-induced catalepsy. TRH, administered subcutaneously, exhibited little or no anti-cataleptic activity. These results are discussed in relation to the possible central site of narcotic-induced catalepsy and the therapeutic potential of PLG in Parkinson's disease.     

Cholecystokinin in anxiety

Cholecystokinin (CCK) plays an important role in both the alimentary tract and the central nervous system (CNS). At present it seems to be the most abundant neuropeptide in the CNS. This paper reviews the CCK neuronal system and its interactions with γ-aminobutyric acid (GABA) and serotonin (5-hydroxytryptamine; 5-HT). In addition, its putative role in anxiety will be discussed on the basis of animal data and studies in healthy volunteers and panic disorder patients. According to these investigations, the CCK₄ challenge test fulfills most criteria for an ideal panicogenic agent and evidence has been found that CCK_B receptor antagonists might possess anxiolytic properties in man.     

Cholecystokinin, dopamine and schizophrenia

Immunoreactive-cholecystokinin (CCK) in cerebrospinal fluid (CSF) was examined in 11 drug-free DSM-III schizophrenic patients and 6 age-matched controls. CSF CCK was significantly lower (p less than .002) in schizophrenic subjects than in controls and was significantly lower (p less than .01) in male than female schizophrenic subjects. CSF CCK was significantly lower (p less than .04) in schizophrenic subjects whose antipsychotic response was delayed 28 or more days after initiation of haloperidol compared with earlier drug responders. CCK appears to be required for neuroleptic-induced depolarization-inactivation of dopamine neurons and associated antipsychotic response; therefore, schizophrenic patients with low CCK may be resistant to the antipsychotic effects of neuroleptics.     

Adenosine release in morphine-induced hypotension in rats.

1. Following intravenous administration of morphine.HCl a reduction in mean arterial blood pressure (MABP) was produced, quaternary morphine analogue was ineffective. 2. Theophylline and 8-phenyltheophylline administration reduced morphine-induced hypotension. 3. A2 adenosine receptor agonist caused an hypotension while A1 adenosine receptor agonist was ineffective. 4. L-NG-Mono-methylarginine administration reduced the hypotensive effect of exogenous A2 agonist while it was ineffective on morphine-induced hypotension. 5. Morphine-induced hypotension was increased by pretreatment with dipyridamole, whereas tetrabenazine abolished it. 6. The present study is consistent with previous reports on the central hypotensive action of morphine and propose a role for adenosine release in morphine-induced hypotension.     

Antagonism of morphine-induced aversive conditioning by naloxone.

In Experiment 1, 4 doses of morphine and 4 doses of naloxone were tested for their ability to induce a conditioned aversion to saccharin in rats. Morphine was much more potent than naloxone which had only weak effects at the highest dose (12.96 mg/kg). Based on the determinations of Experiment 1, doses of 0.096, 0.96 and 0.6 mg/kg of morphine in a second experiment. The highest dose of naloxone was an effective antagonist of morphine-induced aversion. The antagonism was incomplete, but this may have reflected the particular dose combinations that were employed. Although 12.96 mg/kg of naloxone induced only a weak conditioned aversion to saccharin in Experiment 1, 9.6 mg/kg had a substantial effect in Experiment 2. Thus naloxone was itself an agent of aversive conditioning at a dose which significantly antagonized the aversive effects of morphine. Because of the successful demonstraion of antagonism, it was suggested that there may be common pharmacological mechanisms involved in both positive reinforcement and aversive conditioning by drugs of the opiate class.     

Cholecystokinin protects cholinergic neurons against basal forebrain lesion.

Alzheimer's Disease (AD) patients have a severe degeneration of cholinergic neurons in their cerebral cortices. Basal forebrain (BF)-lesioned rat is used as a model animal of a cholinergic deficit in the cerebral cortex. Cholinergic markers were decreased in the cerebral cortex of BF-lesioned rats. Intracerebroventricular continuous infusion of cholecystokinin octapeptide (CCK8) following BF lesion obviously preserved these cholinergic markers. These results suggest that CCK8 prevents the degeneration of cholinergic neurons in the cerebral cortex following BF lesion.     

Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams

A series of 1,3-substituted benzolactams are reported that are potent nonpeptidal antagonists of the peptide hormone cholecystokinin (CCK). Design considerations were based upon the natural product CCK antagonist asperlicin and the potent benzodiazepine antagonist series exemplified by L-364,718 (1). Compound 19, the most potent compound in the benzolactam series, had an IC50 = 3 nM for inhibition of binding of 125I-CCK-8 to CCK receptors in rat pancreatic tissue, and its racemic analogue 8 was found to be orally active in inhibiting CCK-induced gastric emptying in mice, with an ED50 = 2.6 mg/kg po. The effects of ring size, substitution at positions 1 and 3, and stereochemistry at position 3 are discussed. Conformational studies of compound 19 and L-364,718 have delineated similarities that these molecules share in their core conformations and substituent orientations.